Comparison of Patient Characteristics and Anti-VEGF Utilization during the First Year of Treatment.

Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration

O.M. Blavatska
T.B. Kustryn
A.R. Korol

February 2018

Purpose: To compare morphometric changes in the chorioretinal complex after anti-vascular endothelia...

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes

Alessandro Arrigo
Andrea Saladino
Emanuela Aragona
Stefano Mercuri
Ugo Introini
Francesco Bandello
Maurizio Battaglia Parodi

January 2021

Purpose. To evaluate the effects of anti-VEGF treatment of neovascular age-related macular degenerat...

Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration

Charles C. Wykoff, MD, PhD
Vincent Garmo, MHS
David Tabano, PhD
Alicia Menezes, MD
Eunice Kim, RPh, MS
Helene B. Fevrier, MSm
Andrew LaPrise, BS
Theodore Leng, MD, MS

March 2024

Purpose: To evaluate anti-VEGF treatment patterns and the influence of patient demographic and clini...

Cumulative number of Anti-vascular endothelial growth factor (anti-VEGF) injections and follow-up visits to month 12, comparing eyes with Age-related Macular Degeneration (AMD-CNV) and Polypoidal Choroidal Vasculopathy (PCV).

Chui Ming Gemmy Cheung (307768)
Xiang Li (114679)
Ranjana Mathur (590514)
Shu Yen Lee (87527)
Choi Mun Chan (590515)
Ian Yeo (590516)
Boon Kwang Loh (590517)
Rachel Williams (372509)
Edmund Yick-Mun Wong (590518)
Doric Wong (590519)
Tien Yin Wong (417969)

June 2014

*P value based on Wilcoxon rank sum test.AMD-age-related macular degeneration, PCV- polypo...

Initial Treatment Pattern from Baseline to Month 3, comparing eyes with Age-related Macular Degeneration (AMD-CNV) and Polypoidal Choroidal Vasculopathy (PCV).

Chui Ming Gemmy Cheung (307768)
Xiang Li (114679)
Ranjana Mathur (590514)
Shu Yen Lee (87527)
Choi Mun Chan (590515)
Ian Yeo (590516)
Boon Kwang Loh (590517)
Rachel Williams (372509)
Edmund Yick-Mun Wong (590518)
Doric Wong (590519)
Tien Yin Wong (417969)

June 2014

* Treatment given before month 3 (inclusive).†P value to test the distribution of initial ...

Forrest plots for the proportion of patients with a loss from baseline in best-corrected visual acuity (BCVA) of greater than or equal to 15 letters on Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at six and twelve months between anti-VEGF and placebo group.

Peirong Huang (501361)
Wenquan Niu (118888)
Zhentian Ni (501362)
Renzuo Wang (501363)
Xiaodong Sun (166163)

December 2013

Forrest plots for the proportion of patients with a loss from baseline in best-corrected visual a...

Forrest plots for the mean visual acuity change on Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at one, six and twelve months between anti-VEGF and placebo group.

Peirong Huang (501361)
Wenquan Niu (118888)
Zhentian Ni (501362)
Renzuo Wang (501363)
Xiaodong Sun (166163)

December 2013

Forrest plots for the mean visual acuity change on Early Treatment in Diabetic Retinopathy Study ...

Forrest plots for the proportion of patients with an improvement from baseline in best-corrected visual acuity (BCVA) of greater than or equal to 15 letters on Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at six and twelve months between anti-VEGF and placebo group.

Peirong Huang (501361)
Wenquan Niu (118888)
Zhentian Ni (501362)
Renzuo Wang (501363)
Xiaodong Sun (166163)

December 2013

Forrest plots for the proportion of patients with an improvement from baseline in best-corrected ...

Annual Mean Number of Injections With any Anti-VEGF Treatment and Annual Mean Number of Non-injection Visits in The First Year of Therapy in Patients Starting Treatment with Ranibizumab or Aflibercept for Management of nAMD.

Alberto Ferreira (590387)
Alexandros Sagkriotis (775224)
Melvin Olson (775225)
Jingsong Lu (732560)
Charles Makin (585729)
Fran Milnes (775226)

July 2015

Results are not adjusted for bilateral treatment and include patients who may have changed to ano...

Level of CCR2, CX3CR1, CCL2 and CX3CL1 according to clinical response to anti-VEGF treatment.

Mads Krüger Falk (438786)
Amardeep Singh (438785)
Carsten Faber (414192)
Mogens Holst Nissen (674886)
Thomas Hviid (674887)
Torben Lykke Sørensen (438788)

December 2014

Patients with neovascular AMD in active treatment with anti-VEGF were divided in groups according...

Distribution of Initial Treatment Modalities by diagnosis of Age-related Macular Degeneration (AMD-CNV) (left) and Polypoidal Choroidal Vasculopathy (PCV) (right).

Chui Ming Gemmy Cheung (307768)
Xiang Li (114679)
Ranjana Mathur (590514)
Shu Yen Lee (87527)
Choi Mun Chan (590515)
Ian Yeo (590516)
Boon Kwang Loh (590517)
Rachel Williams (372509)
Edmund Yick-Mun Wong (590518)
Doric Wong (590519)
Tien Yin Wong (417969)

June 2014

Distribution of Initial Treatment Modalities by diagnosis of Age-related Macular Degeneration (AM...

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies.

Clearkin, Louis
Ramasamy, Balasubramanian
Wason, James
Tiew, Stephenie

January 2019

Objective: Clear information is essential to properly determine preference in medical intervention. ...

AMD Expert Column Series Comparison of Recent AMD Clinical Trials: An Evidence- Based Approach to Treating AMD Patients

Peter K. Kaiser

August 2016

Age-related macular degeneration (AMD) is the leading cause of blindness in patients over the age of...

Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment

Demetrios G. Vavvas
Anthony B. Daniels
Zoi G. Kapsala
Jeremy W. Goldfarb
Emmanuel Ganotakis
John I. Loewenstein
Lucy H. Young
Evangelos S. Gragoudas
Dean Eliott
Ivana K. Kim
Miltiadis K. Tsilimbaris
Joan W. Miller

March 2016

Importance: Age-related macular degeneration (AMD) remains the leading cause of blindness in develop...

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD

Miltiadis K. Tsilimbaris
Maria I. López-Gálvez
Roberto Gallego-Pinazo
Philippe Margaron
George N. Lambrou

January 2016

Purpose. To review the current literature investigating patient response to antivascular endothelial...

Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration

O.M. Blavatska
T.B. Kustryn
A.R. Korol

February 2018

Purpose: To compare morphometric changes in the chorioretinal complex after anti-vascular endothelia...

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes

Alessandro Arrigo
Andrea Saladino
Emanuela Aragona
Stefano Mercuri
Ugo Introini
Francesco Bandello
Maurizio Battaglia Parodi

January 2021

Purpose. To evaluate the effects of anti-VEGF treatment of neovascular age-related macular degenerat...

Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration

Charles C. Wykoff, MD, PhD
Vincent Garmo, MHS
David Tabano, PhD
Alicia Menezes, MD
Eunice Kim, RPh, MS
Helene B. Fevrier, MSm
Andrew LaPrise, BS
Theodore Leng, MD, MS

March 2024

Purpose: To evaluate anti-VEGF treatment patterns and the influence of patient demographic and clini...

Cumulative number of Anti-vascular endothelial growth factor (anti-VEGF) injections and follow-up visits to month 12, comparing eyes with Age-related Macular Degeneration (AMD-CNV) and Polypoidal Choroidal Vasculopathy (PCV).

Chui Ming Gemmy Cheung (307768)
Xiang Li (114679)
Ranjana Mathur (590514)
Shu Yen Lee (87527)
Choi Mun Chan (590515)
Ian Yeo (590516)
Boon Kwang Loh (590517)
Rachel Williams (372509)
Edmund Yick-Mun Wong (590518)
Doric Wong (590519)
Tien Yin Wong (417969)

June 2014

*P value based on Wilcoxon rank sum test.AMD-age-related macular degeneration, PCV- polypo...

Initial Treatment Pattern from Baseline to Month 3, comparing eyes with Age-related Macular Degeneration (AMD-CNV) and Polypoidal Choroidal Vasculopathy (PCV).

Chui Ming Gemmy Cheung (307768)
Xiang Li (114679)
Ranjana Mathur (590514)
Shu Yen Lee (87527)
Choi Mun Chan (590515)
Ian Yeo (590516)
Boon Kwang Loh (590517)
Rachel Williams (372509)
Edmund Yick-Mun Wong (590518)
Doric Wong (590519)
Tien Yin Wong (417969)

June 2014

* Treatment given before month 3 (inclusive).†P value to test the distribution of initial ...

Forrest plots for the proportion of patients with a loss from baseline in best-corrected visual acuity (BCVA) of greater than or equal to 15 letters on Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at six and twelve months between anti-VEGF and placebo group.

Peirong Huang (501361)
Wenquan Niu (118888)
Zhentian Ni (501362)
Renzuo Wang (501363)
Xiaodong Sun (166163)

December 2013

Forrest plots for the proportion of patients with a loss from baseline in best-corrected visual a...

Forrest plots for the mean visual acuity change on Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at one, six and twelve months between anti-VEGF and placebo group.

Peirong Huang (501361)
Wenquan Niu (118888)
Zhentian Ni (501362)
Renzuo Wang (501363)
Xiaodong Sun (166163)

December 2013

Forrest plots for the mean visual acuity change on Early Treatment in Diabetic Retinopathy Study ...

Forrest plots for the proportion of patients with an improvement from baseline in best-corrected visual acuity (BCVA) of greater than or equal to 15 letters on Early Treatment in Diabetic Retinopathy Study (ETDRS) Chart at six and twelve months between anti-VEGF and placebo group.

Peirong Huang (501361)
Wenquan Niu (118888)
Zhentian Ni (501362)
Renzuo Wang (501363)
Xiaodong Sun (166163)

December 2013

Forrest plots for the proportion of patients with an improvement from baseline in best-corrected ...

Annual Mean Number of Injections With any Anti-VEGF Treatment and Annual Mean Number of Non-injection Visits in The First Year of Therapy in Patients Starting Treatment with Ranibizumab or Aflibercept for Management of nAMD.

Alberto Ferreira (590387)
Alexandros Sagkriotis (775224)
Melvin Olson (775225)
Jingsong Lu (732560)
Charles Makin (585729)
Fran Milnes (775226)

July 2015

Results are not adjusted for bilateral treatment and include patients who may have changed to ano...

Level of CCR2, CX3CR1, CCL2 and CX3CL1 according to clinical response to anti-VEGF treatment.

Mads Krüger Falk (438786)
Amardeep Singh (438785)
Carsten Faber (414192)
Mogens Holst Nissen (674886)
Thomas Hviid (674887)
Torben Lykke Sørensen (438788)

December 2014

Patients with neovascular AMD in active treatment with anti-VEGF were divided in groups according...

Distribution of Initial Treatment Modalities by diagnosis of Age-related Macular Degeneration (AMD-CNV) (left) and Polypoidal Choroidal Vasculopathy (PCV) (right).

Chui Ming Gemmy Cheung (307768)
Xiang Li (114679)
Ranjana Mathur (590514)
Shu Yen Lee (87527)
Choi Mun Chan (590515)
Ian Yeo (590516)
Boon Kwang Loh (590517)
Rachel Williams (372509)
Edmund Yick-Mun Wong (590518)
Doric Wong (590519)
Tien Yin Wong (417969)

June 2014

Distribution of Initial Treatment Modalities by diagnosis of Age-related Macular Degeneration (AM...

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies.

Clearkin, Louis
Ramasamy, Balasubramanian
Wason, James
Tiew, Stephenie

January 2019

Objective: Clear information is essential to properly determine preference in medical intervention. ...

AMD Expert Column Series Comparison of Recent AMD Clinical Trials: An Evidence- Based Approach to Treating AMD Patients

Peter K. Kaiser

August 2016

Age-related macular degeneration (AMD) is the leading cause of blindness in patients over the age of...

Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment

Demetrios G. Vavvas
Anthony B. Daniels
Zoi G. Kapsala
Jeremy W. Goldfarb
Emmanuel Ganotakis
John I. Loewenstein
Lucy H. Young
Evangelos S. Gragoudas
Dean Eliott
Ivana K. Kim
Miltiadis K. Tsilimbaris
Joan W. Miller

March 2016

Importance: Age-related macular degeneration (AMD) remains the leading cause of blindness in develop...

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD

Miltiadis K. Tsilimbaris
Maria I. López-Gálvez
Roberto Gallego-Pinazo
Philippe Margaron
George N. Lambrou

January 2016

Purpose. To review the current literature investigating patient response to antivascular endothelial...

Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration

O.M. Blavatska
T.B. Kustryn
A.R. Korol

February 2018

Purpose: To compare morphometric changes in the chorioretinal complex after anti-vascular endothelia...

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes

Alessandro Arrigo
Andrea Saladino
Emanuela Aragona
Stefano Mercuri
Ugo Introini
Francesco Bandello
Maurizio Battaglia Parodi

January 2021

Purpose. To evaluate the effects of anti-VEGF treatment of neovascular age-related macular degenerat...

Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration

Charles C. Wykoff, MD, PhD
Vincent Garmo, MHS
David Tabano, PhD
Alicia Menezes, MD
Eunice Kim, RPh, MS
Helene B. Fevrier, MSm
Andrew LaPrise, BS
Theodore Leng, MD, MS

March 2024

Purpose: To evaluate anti-VEGF treatment patterns and the influence of patient demographic and clini...

Comparison of Patient Characteristics and Anti-VEGF Utilization during the First Year of Treatment.

Abstract

Extracted data

Comparison of Patient Characteristics and Anti-VEGF Utilization during the First Year of Treatment.

Abstract

Extracted data

Related items

Related items